Signed a CMO contract worth ‘KRW 1.7028 trillion’ with an Asian company
Customer privacy… Industry: “Contract with affiliate Samsung Bioepis”
New order performance record in 3 months since last July
Achievement in receiving large orders, nearly half of last year’s annual orders
A total of 9 contracts this year, totaling KRW 4.36 trillion in annual cumulative orders.
↑ Global orders based on excellent production capacity and quality competitiveness
Samsung BioLogics announced in a public notice on the 22nd that it signed a consignment manufacturing (CMO) contract worth approximately KRW 1.7028 trillion (USD 1.24256 billion) with a pharmaceutical company in Asia. This is the largest order received ever and is close to half of last year’s total annual orders (KRW 3.5 trillion).
In particular, following the signing of a contract worth approximately 1.46 trillion won with a U.S.-based pharmaceutical company last July, the company set a new record for the largest order intake in history in just three months. Accordingly, the cumulative annual order amount this year has already exceeded 4 trillion won. It is also a performance that exceeds last year by more than 20%. With more than two months left in the year, Samsung BioLogics is recording a cumulative annual order receipt of approximately 4.36 trillion won through a total of 9 contracts. Depending on the strategy, annual orders could exceed 5 trillion won.
It is said that the names of the customers and products have been decided not to be disclosed by establishing a non-disclosure agreement (NDA). The contract period is until December 31, 2037. Although the customer company was not disclosed, some in the industry believe that the target of this ultra-large long-term contract is its affiliate, Samsung Bioepis.
Samsung BioLogics is working to expand production capacity to meet the increasing demand for biopharmaceuticals. Following Plant 4, the latest facility, Plant 5 with an annual capacity of 180,000 liters is under construction with the goal of operating in April next year. Upon completion of Plant 5, Samsung BioLogics will have a total annual production capacity of 784,000 liters.
The batch success rate, which is a standard for pharmaceutical quality, increased from 98% last year to 99%. It is evaluated as demonstrating excellent quality competitiveness throughout the entire pharmaceutical manufacturing and management process with the world’s highest placement success rate. In addition, a total of 326 cases (39 from the U.S. Food and Drug Administration, 34 from the European Medicines Agency, etc.) were secured for manufacturing approval from global regulatory agencies, thereby differentiating the reliability of the manufactured drugs. Manufacturing approval is expected to continue to increase as pharmaceutical production volume increases and facility expansion increases.
Based on these capabilities, Samsung BioLogics currently has 17 of the top 20 global pharmaceutical companies as customers. Thanks to core order competitiveness such as overwhelming production capacity, quality competitiveness, and multiple track records, the total cumulative order amount since its inception has exceeded approximately KRW 21.2535 trillion (USD 15.4 billion).
Based on differentiated biopharmaceutical technology, we are continuously strengthening our platform-based contract development (CDO) service, which is considered a high value-added business. ‘S-AfuCHO’, which increases the anti-cancer effect of antibodies, ‘S-OptiCharge’, a high-quality protein production support platform, and ‘S-Tensify’, a high-concentration cell culture development support platform, etc. This year alone, three new CDO platforms were introduced. Samsung BioLogics has a total of 9 biopharmaceutical technology platforms, including 4 CDO platforms.
Meanwhile, Samsung BioLogics is actively participating in large-scale pharmaceutical and bio industry conferences held on the global stage in the United States, Europe, and Asia this year. The purpose is to strengthen order-taking activities while promoting brand competitiveness. The ‘BIO International Convention’ held in San Diego, USA last June, the ‘CPHI Worldwide 2024 (Convention on Pharmaceutical Ingredients Worldwide 2024)’ held in Milan this month, and the ‘BIO JAPAN 2024′ held in Yokohama, Japan. )’ and operated a booth.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog